|Systematic (IUPAC) name|
|Biological half-life||16.2 hours|
|Excretion||Faecal / Renal (approx. 75%/22%)|
|Molecular mass||1570.4 g/mol|
|(what is this?)|
Ganirelix acetate (or diacetate) is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovulation. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. Ganirelix is used in fertility treatment to prevent premature ovulation that could result in the harvesting of eggs that are too immature to be used in procedures such as in vitro fertilisation.
GnRH agonists are also sometimes used in reproductive therapy, as well as to treat disorders involving sex-steroid hormones, such as endometriosis. One advantage of using GnRH antagonists is that repeated administration of GnRH agonists results in decreased levels of gonadotropins and sex steroids due to desensitization of the pituitary. This is avoided when using GnRH antagonists such as Ganirelix. The success of Ganirelix in reproductive therapy has been shown to be comparable to that when using GnRH agonists.
Ganirelix is derived from GnRH itself, with amino acid substitutions made at positions 1, 2, 3, 6, 8, and 10.
Ganirelix is used as a fertility treatment drug for women. Specifically, it is used to prevent premature ovulation in women undergoing fertility treatment involving ovarian hyperstimulation that causes the ovaries to produce multiple eggs. When such premature ovulation occurs, the eggs released by the ovaries may be too immature to be used in in-vitro fertilisation. Ganirelix prevents ovulation until it is triggered by injecting human chorionic gonadotrophin (hCG).
When Ganirelix is given to healthy adult females, steady-state serum concentrations are reached, on average, after three days ("Ganirelix acetate injection," 2009). A study administering Ganirelix to healthy adult females (n=15) found the mean (SD) elimination half-life (t1/2) to be 16.2(1.6) hours, volume of distribution/absolute bioavailability (Vd/F) 76.5(10.3) liters, maximum serum concentration (Cmax) 11.2(2.4) ng/mL, and the time until maximum concentration (tmax) 1.1(0.2) hours. One 250 µg injection of Ganirelix resulted in a mean absolute bioavailability of 91.1%.
Ganierlix is a synthetic peptide that works as an antagonist against gonadotropin-releasing hormone (GnRH) ("Ganirelix acetate injection," 2009). Ganirelix competitively blocks GnRH receptors on the pituitary gonadotroph, quickly resulting in the suppression of gonadotropin secretion. This suppression is easily reversed by discontinuation of Ganirelix administration. Ganirelix has a significantly higher receptor binding affinity (Kd = 0.4 nM) than GnRH (Kd = 3.6 nM).
Dosage and Administration
Ganirelix is administered by a subcutaneous injection of 250 µg once per day during the mid to late follicular phase of a woman’s menstrual cycle. Treatment should start on the 5th or 6th day after the start of ovarian stimulation, and the mean duration for its use is five days. Preferably, the subcutaneous injections are delivered in the upper leg, and the patient can be trained to do this herself. Continued use of the drug should take place until the administration of hCG begins. hCG administration is begun when a sufficient number of follicles have developed due to the effects of endogenous and or exogenously administered follicle stimulating hormone.
Clinical studies have shown that the most common side effect is a slight reaction at the site of injection in the form of redness, and sometimes swelling. Clinical studies have shown that, one hour after injection, the incidence of at least one moderate or severe local skin reaction per treatment cycle was 12% in 4 patients treated with Ganirelix and 25% in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear within 4 hours after administration. Other reported side effects are some that are known to be associated with ovarian hyperstimulation, including gynecological abdominal pain, headache, vaginal bleeding, nausea, and gastrointestinal abdominal pain. In some rare cases, less than 1 user in 10,000, hypersensitivity to Ganirelix can cause anaphylactoid reactions, most likely due to allergy.
Implications for Pregnancy
A follow-up analysis for Ganirelix done by the Marketing Authorisation Holder compared the number of congenital malformations between individuals whose mothers were treated with Ganirelix compared with individuals whose mothers were treated with a GnRH agonist. The total number of congenital malformations was higher in the ganirelix group than in the GnRH agonist group (7.6% vs. 5.5%). This falls within the range for the normal incidence of congenital malformations, and current data do not suggest that Ganirelix increases the incidence of congenital malformations or anomalies. No important differences in the frequency of ectopic pregnancies and miscarriage were noted with the use of Ganirelix.
Ganirelix should not be used in women who are already pregnant, and because of this the onset of pregnancy must be ruled out before it is administered. Women using Ganirelix should not breast feed, as it is not known whether Ganirelix is excreted in breast milk.
Currently, no studies have been done to assess the possible drug-drug interactions between Ganirelix and other drugs.
- European Medicines Agency. "Orgalutran". Retrieved 11 May 2012.
- Oberyé, J; Mannaerts, B; Huisman, J; Timmer, C (February 2000). "Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections.". Human reproduction (Oxford, England) 15 (2): 245–9. doi:10.1093/humrep/15.2.245. PMID 10655292.
- Organon Pharmaceuticals USA. "Ganirelix Acetate Injection". Archived Drug Label. Retrieved 11 May 2012.
- European Medicines Agency. "Orgalutran : EPAR – Scientific Discussion". Retrieved 13 May 2012.